Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...
GUILDFORD, UK / ACCESSWIRE / November 9, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in ...
Epidemiological characteristics of gastric and pancreatic cancers in Latin America: GASPAR (LACOG 0222) study. Comparison of long-term outcomes for neoadjuvant chemoradiation (NA-CRT) followed by ...
Amini: This varies quite a bit by stage — operable vs. nonoperable — and patients’ performance status and preference. Additionally, more relevant to medical oncology but equally, if not more, ...
Jonathan Thompson, MD, MS, emphasized that comprehensive biomarker testing with next-generation sequencing and PD-L1 analysis—implemented as reflex testing at biopsy—is essential to guide precision ...
L1, EBV and mismatch repair deficiency suggests CLDN18.2 stratification must be integrated into multi-biomarker algorithms ...
Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a one-size-fits-all approach. Biomarkers serve diagnostic, prognostic, and predictive roles ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results